Home LiteratureArticle Details
PMID: 17362670 Published · ppublish English Comment Journal Article

Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension.

Current hypertension reports ·Vol. 9 ·No. 1 ·2007-03-00 ·Pages 41-4

Ruschitzka F

Abstract

暂无摘要

Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Ruschitzka Frank
Department of Cardiology, University Hospital, Zurich, Switzerland. frankruschitzka@yahoo.com
References (18)
18 references, click to expand
  1. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    N Engl J Med. 2005 Mar 17;352(11):1092-102 PMID: 15713943
  2. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Biochem Pharmacol. 2004 Jul 15;68(2):341-50 PMID: 15194006
  3. Non-narcotic analgesic dose and risk of incident hypertension in US women.
    Hypertension. 2005 Sep;46(3):500-7 PMID: 16103274
  4. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    JAMA. 2000 Sep 13;284(10):1247-55 PMID: 10979111
  5. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Circulation. 2003 Nov 11;108(19):2308-11 PMID: 14597594
  6. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Lancet. 2004 May 29;363(9423):1751-6 PMID: 15172772
  7. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
    Circulation. 2006 Sep 5;114(10):1028-35 PMID: 16943394
  8. To the heart of the matter: coxibs, smoking, and cardiovascular risk.
    Circulation. 2005 Aug 16;112(7):941-5 PMID: 16103251
  9. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
    Hypertension. 2003 Sep;42(3):310-5 PMID: 12874094
  10. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Hypertension. 2005 Jan;45(1):92-7 PMID: 15545508
  11. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet. 2006 Nov 18;368(9549):1771-81 PMID: 17113426
  12. Selective COX-2 inhibition improves endothelial function in coronary artery disease.
    Circulation. 2003 Jan 28;107(3):405-9 PMID: 12551863
  13. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.
    Circulation. 2005 Apr 5;111(13):1685-9 PMID: 15795326
  14. Relationship between COX-2 specific inhibitors and hypertension.
    Hypertension. 2004 Aug;44(2):140-5 PMID: 15226279
  15. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    N Engl J Med. 2005 Mar 17;352(11):1071-80 PMID: 15713944
  16. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Arch Intern Med. 2005 Jan 24;165(2):161-8 PMID: 15668361
  17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528 PMID: 11087881
  18. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Lancet. 2005 Feb 5-11;365(9458):475-81 PMID: 15705456
Article Info
Journal
Current hypertension reports
Abbr.
Curr Hypertens Rep
ISSN
1522-6417
DOI
10.1007/s11906-007-0008-4
Email
frankruschitzka@yahoo.com
Published
2007-03-00
Pages
41-4
Language
English
Region
United States
NLM ID
100888982
Corrections
CommentOn
PMID: 16968832
External Links
PubMed source DOI: 10.1007/s11906-007-0008-4 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2